<SUBMISSION>
<ACCESSION-NUMBER>0000950137-05-013820
<TYPE>8-K
<PUBLIC-DOCUMENT-COUNT>3
<PERIOD>20051110
<ITEMS>2.02
<ITEMS>9.01
<FILING-DATE>20051114
<DATE-OF-FILING-DATE-CHANGE>20051114
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>BIOSANTE PHARMACEUTICALS INC
<CIK>0001023024
<ASSIGNED-SIC>2836
<IRS-NUMBER>582301143
<STATE-OF-INCORPORATION>DE
<FISCAL-YEAR-END>1231
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>8-K
<ACT>34
<FILE-NUMBER>001-31812
<FILM-NUMBER>051201646
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>111 BARCLAY BLVD STE 280
<CITY>LINCOLNSHIRE
<STATE>IL
<ZIP>60069
<PHONE>8474780500
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>111 BARCLAY BLVD STE 280
<CITY>LINCOLNSHIRE
<STATE>IL
<ZIP>60069
</MAIL-ADDRESS>
<FORMER-COMPANY>
<FORMER-CONFORMED-NAME>BEN ABRAHAM TECHNOLOGIES INC
<DATE-CHANGED>19991027
</FORMER-COMPANY>
</FILER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>c00019e8vk.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<HTML>
<HEAD>
<TITLE>e8vk</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 1pt solid black; font-size: 1pt">&nbsp;</DIV>






<DIV align="center" style="font-size: 14pt; margin-top: 12pt"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION</B>
</DIV>

<DIV align="center" style="font-size: 12pt"><B>Washington, D.C. 20549</B>
</DIV>


<DIV align="center">
<DIV style="font-size: 3pt; margin-top: 16pt; width: 26%; border-top: 1px solid #000000">&nbsp;</DIV>
</DIV>



<DIV align="center" style="font-size: 18pt; margin-top: 12pt"><B>FORM 8-K</B>
</DIV>


<DIV align="center" style="font-size: 12pt; margin-top: 12pt"><B>Current Report<BR>
Pursuant to Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934</B>
</DIV>


<DIV align="center">
<DIV style="font-size: 3pt; margin-top: 16pt; width: 26%; border-top: 1px solid #000000">&nbsp;</DIV>
</DIV>




<DIV align="center" style="font-size: 10pt; margin-top: 18pt">Date of Report (Date of earliest event reported):<BR>
<B>November&nbsp;10, 2005</B>
</DIV>

<DIV align="center" style="font-size: 24pt; margin-top: 12pt"><B>BIOSANTE PHARMACEUTICALS, INC.</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(Exact name of registrant as specified in its charter)
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="31%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="31%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="31%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><B>Delaware</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>1-31812</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>58-2301143</B></TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top">(State or Other Jurisdiction of
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(Commission File Number)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(I.R.S. Employer Identification</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top">Incorporation</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Number)</TD>
</TR>
<TR valign="bottom">
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD align="center" valign="top"><B>111 Barclay Boulevard</B></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><B>Lincolnshire, Illinois</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>60069</B></TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top">(Address of Principal Executive Offices)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(Zip Code)</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>(847)&nbsp;478-0500</B><BR>
(Registrant&#146;s Telephone Number, Including Area Code)
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>N/A</B><BR>
(Former Name or Former Address, If Changed Since Last Report)
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><FONT style="font-family: Wingdings 2">&#163;</FONT> Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><FONT style="font-family: Wingdings 2">&#163;</FONT> Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12)
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><FONT style="font-family: Wingdings 2">&#163;</FONT> Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><FONT style="font-family: Wingdings 2">&#163;</FONT> Pre-commencement communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
</DIV>

<DIV style="width: 100%; border-bottom: 1pt solid black; margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>






<P align="center" style="font-size: 10pt">&nbsp;
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">








<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Section&nbsp;2 &#150; Financial Information</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Item&nbsp;2.02. Results of Operations and Financial Condition</B>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On November&nbsp;10, 2005, BioSante Pharmaceuticals, Inc. publicly announced its product
development highlights and financial results for the third quarter ended September&nbsp;30, 2005. For
further information, please refer to the press release attached hereto as Exhibit&nbsp;99.1, which is
incorporated by reference herein.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The information contained in this report and the exhibit hereto shall not be deemed to be
&#147;filed&#148; for purposes of Section&nbsp;18 of the Securities Exchange Act of 1934, as amended, and shall
not be incorporated by reference into any filings made by BioSante Pharmaceuticals, Inc. under the
Securities Act of 1933, as amended, or the Exchange Act, except as may be expressly set forth by
specific reference in such filing.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Section&nbsp;9 &#150; Financial Statements and Exhibits</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Item&nbsp;9.01. Financial Statements and Exhibits.</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;<I>Exhibits</I>.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="90%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="9%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="88%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left"><U>Exhibit No.</U></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left"><U>Description</U></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">99.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Press Release issued November&nbsp;10, 2005</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt">&nbsp;
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>SIGNATURE</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
</DIV>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left"><B>BIOSANTE PHARMACEUTICALS, INC.</B><BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Phillip B. Donenberg
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Phillip B. Donenberg</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left"><I>Chief Financial Officer, Treasurer and Secretary</I>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Dated: November&nbsp;11, 2005

</DIV>

<P align="center" style="font-size: 10pt">&nbsp;
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>BIOSANTE PHARMACEUTICALS, INC.</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>FORM 8-K</B><BR>
<U><B>Exhibit&nbsp;Index</B></U>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="6%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="69%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="19%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left"><B><U>Exhibit No.</U></B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left"><B><U>Description</U></B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center"><B><U>Method of Filing</U></B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">99.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Press Release issued November&nbsp;10, 2005
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Filed herewith</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt">&nbsp;
</DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>c00019exv99w1.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML>
<HEAD>
<TITLE>exv99w1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;99.1</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="70%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>&nbsp;</B></TD>
</TR>

<TR valign="top">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="top">

<TD rowspan="6" valign="top"><DIV style="margin-left:0px; text-indent:-0px"><IMG src="c00019c0001901.gif" alt="(BIOSANTE LOGO)">
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;
</TD>
</TR>
<TR valign="top">

<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD align="left" valign="top"><B>BioSante Pharmaceuticals,
Inc.</B><BR>
111 Barclay Boulevard<BR>
Lincolnshire, Illinois 60069<BR>
www.biosantepharma.com
</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">
</DIV></TD>

    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">
</DIV></TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><DIV style="border-bottom: 1px solid #000000; font-size: 1px">&nbsp;</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="23%">&nbsp;</TD>
    <TD width="50%">&nbsp;</TD>
    <TD width="17%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>FOR IMMEDIATE RELEASE</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>Amex: BPA</B></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>BioSante Pharmaceuticals Reports Product Development Highlights<BR>
and Third Quarter 2005 Financial Results</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>LINCOLNSHIRE, Illinois (November&nbsp;10, 2005) &#150;</B>BioSante Pharmaceuticals, Inc. (AMEX: BPA) today
reported product development highlights and financial results for the third quarter ended September
30, 2005.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&#147;We achieved milestones across our key clinical programs this quarter. We presented positive Phase
III data for Bio-E-Gel<SUP style="font-size: 85%; vertical-align: text-top">&#153;</SUP>, licensed three patents that cover the use of testosterone
(LibiGel&#153;) to treat hypoactive sexual desire disorder in women on hormone contraception, and
entered into an allergy licensing option agreement for our CaP nanotechnology,&#148; said Stephen M.
Simes, BioSante&#146;s president and chief executive officer. &#147;We continue to prepare our New Drug
Application for Bio-E-Gel. Regarding LibiGel, we are using recent updated guidance from the FDA
for testosterone-based products in defining our Phase III protocols, and expect to initiate Phase
III clinical studies of LibiGel in the first quarter of 2006.&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Product and Corporate Highlights</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>BioSante presented Phase III clinical data on Bio-E-Gel (bio-identical estradiol gel) at
the North American Menopause Society (NAMS)&nbsp;annual meeting in San Diego. Results from the
484-patient study identified three effective doses as well as the lowest effective dose.
In the study, Bio-E-Gel significantly decreased the number of hot flashes by 88&nbsp;percent,
from 12.9 per day at baseline to 1.6 after treatment (p&#060;0.0001). The decrease was also
significant versus placebo, with a mean decrease of 11.3 hot flashes per day with Bio-E-Gel
versus a decrease of 6.1 with placebo (p&#060;0.0001). Bio-E-Gel produced low estradiol
blood levels and had a safety profile similar to that observed in the placebo group.
Notably, there was minimal application site irritation reported, a side effect known to be
associated with transdermal patches.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>BioSante signed a worldwide license agreement with Wake Forest University Health
Sciences and Cedars Sinai Medical Center covering three patents encompassing triple hormone
contraception technology, a novel combination of estrogens and progestins with androgens.
BioSante plans to study LibiGel<SUP style="font-size: 85%; vertical-align: text-top"> </SUP>(bioidentical testosterone gel) as the androgen
component to help restore sexual desire and activity to women taking traditional oral
contraceptives who have experienced this side effect. Financial terms include regulatory
milestone payments, maintenance payments and royalty payments if a product incorporating
the licensed technology is approved and subsequently marketed. In a Phase II study of
LibiGel in surgically menopausal women, LibiGel was shown to increase the number of
satisfying sexual events by 238&nbsp;percent. This increase was statistically significant
compared to baseline and placebo.
</TD>
</TR>
</TABLE>
</DIV>
<P align="center" style="font-size: 10pt">&nbsp;
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In September, BioSante signed a Material Transfer and Option Agreement for an exclusive
option to obtain a license to use BioSante&#146;s calcium phosphate nanotechnology (CaP) in the
development of a series of allergy products. The undisclosed European partner company will
fund its development of potential products for the treatment of conditions including
rhinitis, asthma, conjunctivitis, dermatitis, and allergic gastrointestinal diseases.
BioSante received a non-refundable $250,000 upfront payment, and could potentially receive
more than $10&nbsp;million dollars in additional maintenance, milestone and royalty payments if
the option is exercised and the parties enter into an exclusive license agreement.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Third Quarter 2005 Financial Overview</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">BioSante incurred a net loss of approximately $1.85&nbsp;million, or $(0.10) per share for the quarter
ended September&nbsp;30, 2005, compared to a net loss of approximately $2.87&nbsp;million, or $(0.16) per
share for the third quarter of 2004. For the first nine months of 2005, the Company&#146;s net loss
totaled approximately $7.2&nbsp;million, or $(0.37) per share, compared to a net loss of approximately
$7.89&nbsp;million, or $(0.48) per share, for the first nine months of 2004. As of September&nbsp;30, 2005,
the Company&#146;s cash, cash equivalents and short-term investments were approximately $10.3&nbsp;million.
The Company anticipates a cash burn rate of approximately $600,000 per month for the remainder of
2005.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>About BioSante Pharmaceuticals, Inc.</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">BioSante is developing a pipeline of hormone therapy products to treat both men and women. These
hormone therapy products are gel formulations for transdermal administration that deliver
bioidentical estradiol and testosterone. BioSante&#146;s lead products include Bio-E-Gel<SUP style="font-size: 85%; vertical-align: text-top">&#153;
</SUP>(bioidentical estradiol gel) for the treatment of women with menopausal symptoms, and
LibiGel<SUP style="font-size: 85%; vertical-align: text-top">&#153;</SUP> (bioidentical testosterone gel) for the treatment of female sexual dysfunction
(FSD). The current market in the U.S. for estrogen and testosterone products is approximately $2.5
billion. The transdermal gel formulations used in the women&#146;s gel products are licensed by BioSante
from Antares Pharma Inc. The Company also is developing its calcium phosphate nanotechnology (CaP)
for novel vaccines, including biodefense vaccines for toxins such as anthrax and ricin, and drug
delivery systems. Additional information is available online at: www.biosantepharma.com.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>This news release contains forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. The statements regarding BioSante contained in this press release
that are not historical in nature, particularly those that utilize terminology such as &#147;may,&#148;
&#147;will,&#148; &#147;should,&#148; &#147;likely,&#148; &#147;expects,&#148; &#147;anticipates,&#148; &#147;estimates,&#148; &#147;believes&#148; or &#147;plans,&#148; or
comparable terminology, are forward-looking statements. Forward-looking statements are based on
current expectations and assumptions, and entail various risks and uncertainties that could cause
actual results to differ materially from those expressed in such forward-looking statements.
Important factors known to BioSante that cause actual results to differ materially from those
expressed in such forward-looking statements are the difficulty of developing pharmaceutical
products, obtaining regulatory and other approvals and achieving market acceptance, and other
factors identified and discussed from time to time in BioSante&#146;s filings with the Securities and
Exchange Commission, including those risk factors discussed in BioSante&#146;s most recent quarterly
report on Form 10-Q, which discussion also is incorporated herein by reference. All
forward-looking statements speak only as of the date of this news release. BioSante undertakes no
obligation to update or revise any forward-looking statement, whether as a result of new
information, future events or otherwise.</I>
</DIV>


<P align="center" style="font-size: 10pt">&nbsp;
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>For more information, please contact:</B>
Ritu S. Baral, The Trout Group LLC; (212)&nbsp;477-9007 ext 25; rbaral@troutgroup.com
Daniel Budwick, BMC Communications; (212)&nbsp;477-9007 ext 14; dbudwick@bmccommunications.com
PhillipDonenberg, BioSante Pharmaceuticals; (847)&nbsp;478-0500; donenber@biosantepharma.com
</DIV>



<P align="center" style="font-size: 10pt">&nbsp;
</DIV>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>c00019c0001901.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 c00019c0001901.gif
M1TE&.#=AJ0!%`/<`````````50``J@``_P`D```D50`DJ@`D_P!)``!)50!)
MJ@!)_P!M``!M50!MJ@!M_P"2``"250"2J@"2_P"V``"V50"VJ@"V_P#;``#;
M50#;J@#;_P#_``#_50#_J@#__R0``"0`520`JB0`_R0D`"0D520DJB0D_R1)
M`"1)521)JB1)_R1M`"1M521MJB1M_R22`"225222JB22_R2V`"2V522VJB2V
M_R3;`"3;523;JB3;_R3_`"3_523_JB3__TD``$D`54D`JDD`_TDD`$DD54DD
MJDDD_TE)`$E)54E)JDE)_TEM`$EM54EMJDEM_TF2`$F254F2JDF2_TFV`$FV
M54FVJDFV_TG;`$G;54G;JDG;_TG_`$G_54G_JDG__VT``&T`56T`JFT`_VTD
M`&TD56TDJFTD_VU)`&U)56U)JFU)_VUM`&UM56UMJFUM_VV2`&V256V2JFV2
M_VVV`&VV56VVJFVV_VW;`&W;56W;JFW;_VW_`&W_56W_JFW__Y(``)(`59(`
MJI(`_Y(D`)(D59(DJI(D_Y))`)))59))JI))_Y)M`))M59)MJI)M_Y*2`)*2
M59*2JI*2_Y*V`)*V59*VJI*V_Y+;`)+;59+;JI+;_Y+_`)+_59+_JI+__[8`
M`+8`5;8`JK8`_[8D`+8D5;8DJK8D_[9)`+9)5;9)JK9)_[9M`+9M5;9MJK9M
M_[:2`+:25;:2JK:2_[:V`+:V5;:VJK:V_[;;`+;;5;;;JK;;_[;_`+;_5;;_
MJK;__]L``-L`5=L`JML`_]LD`-LD5=LDJMLD_]M)`-M)5=M)JMM)_]MM`-MM
M5=MMJMMM_]N2`-N25=N2JMN2_]NV`-NV5=NVJMNV_]O;`-O;5=O;JMO;_]O_
M`-O_5=O_JMO___\``/\`5?\`JO\`__\D`/\D5?\DJO\D__])`/])5?])JO])
M__]M`/]M5?]MJO]M__^2`/^25?^2JO^2__^V`/^V5?^VJO^V___;`/_;5?_;
MJO_;____`/__5?__JO___R'Y!```````+`````"I`$4`0`C_``,($$BPX,"#
M`0P21#A0(<*%$!E"C#A1XD.'%"UFW*A1H4>-(#=*JBC0Q+9_*+<I,<&R90D3
M2FRA3"GI($R82CP63,BS(4,W,_]]N[7RI5$3+UNRW-F0:<^G3:,^3>ASH0!)
M,U7JE$AUZLZ151N6N!44Y;=]WO:=#;IMFYNN)F2F-"$0*TT!>/,&,,&V!$\W
MV_:5/4GX7^%MWVI2[-J5[$RZ=;/FQ)O0Y,Q))9I*6JN5H6/#.3%&O$H2K\S"
M^_R5_6:8;6@!,EG[HSM0R<F@DMP`;MU6$FT!DX2B%%RVN.I]BF&SE:/[C>[=
M9[_1#A`\96B!`BR?M/5;P.ZLSR';_\UZ2](D2Y(NR7(S/2'8B0*5R)>?1"G+
ME_/S4\ZNGR#.^284($(!_RGAAA((P61$$BJDL)(*1D`(87[Y446A"2)DIR%+
M%?JG'V4\Y0<93P46Q="%F24E`DL&2/0>5Q3*YT1^!\;(4WP=\@>@5P%0N%.)
M^<T8HQ(J7'01B30BI$)^!5"5%X5Y#51@DQ!1F!EV.T%%G5-/RE@44F`F%:,)
M8H%)YHUH,M048T"&:911!!H%55AZH0E?3VO:>:..\F6XV)T'Z870BUE:LHTV
MA[;55GET'?J6G77B&>5^3`GZD99<!<IEI93Z%*6DU&USRZ=YIOE46V]I6JIF
M&0U$EEMZ#O^$DALV!3=)`$+)H@)+@/DC20DGC620723N\D]R2H!FUTHF&&')
M/FZ==,MSCJT4[$H&WJ)+3(91B])(R6[S"+<CR:2-"MK\8PMS;CCFA@HHO;&K
M@2<!]8\<`4ARBRW,F@"42IK>RE5"CMQ67'&]C1B`",]&]]N>')GJKRV*MG:P
M9)B:&A;$$&LZ6F2":95QIUU5195B!N%E@K'_0'NF14JDFQ*M`1@@5\LC9C?>
M<"FA1%24.]]RI9Z0@GAQ<3]C6=W1+1-5F<'"#3;97C=??,O#^?YI@C7":?/:
M1"9\=JP!"Y,EV#=^*2?4-DX0;?`V23`V)W9YK1P4O@+<<I@DSCW_)PG4TV$5
M\G65L?S/U3U)(ABT7^_U]C:VW++O+;M$;HMO3PF\J9HD*^P5G0Z9X-P;".:Y
MWZ0#:TFT?P:P!.)4EDZ:I9-9-DFJJ2$84((((;BNZI9J6BABQR5=>-"2,[9=
M_(ZS0[GZ:"H;SZ<20AI1PI`T#V1$\DJ0O>=\[$55H.<"#&D^X0.]U[&72MA^
M9(F0"6"$?&H@^/WY`/I4(LFQ9BEC_?@[DX?PES\<$5`$5`'2D#Z5M4"]CH`7
M,D&+(%*@WT$O4A)I'02==[M2E>Q.Q,M4`H<WL-01;2":VY.KNE40$]C%7HG2
MQN"\8QA+Z,9=`3@)M`)CF"1@Q1\5\YEA_VXS$A5P;1N2,,])=J$$LVWC&CR<
M3=@,8YY)&$LELSI("8(CB5W<IBU0?,NKQI*2MLRD>UA!HGEBDZQC7<4PDYB$
M'(+SC4E(1',8U-@'3=8_J7CP2!Z$3R`A9:H]PNY/:QJD(5.72#VJCW8.7(Q%
M4/<0DLDN>*JRI%501[=-1DR$(.&<)D/2*5%V)3FO$X@NF+8:E'CM1E6+W^SD
MQD>J78PU95$-:'B$R(U$;)97^6+C)/E!X@E+4MFY1LO^H0WRD4B&K$D,V:XB
MN<@-C2`JL")BMBFJ[&%G:9"32O\^*+ER3BYRU9S:*<MIN7/>PA+VPXL!RGF;
MLXA*<I808&7:9?].=-YB$M-)'P-Y0D9<#B<Z:B$.3:83EZ#09HHSL8412`0=
ME(0F9@A;9D+MB43V3"1%>ZE9[[B5%80L;1_OBA#U;J'01_%D/*]\BFVR(H<D
M%"`$`KHIE:IRS$YFAV5J&69";(-0H5'E,]N@2T.M<Z>J3:V1G&LB6Y3G'8,>
M#'`$@2GA]I(N:3'T;RUC6\EFVIK%'0QQ@SI20D3`-=4\RH$'^<ZW\%*"T[3,
M+STJ3#.=A)?J;,=(M+Q1"3;#&UI9QF=X1=.K4!(_K+`&8/LY[+$":A?6I.I&
MBC/+94&9U9+IQ0"KA-I,=%F6F*[U,])YG1N4F<N%EBR-+3.H56<B&$G_;'5G
M!U7H3-!V$,'M\D8F0!1*\EDET8+&)F"5K4+1^E*U&G"#'Z),@22EP`L9I+H$
MG&:7H/O4Z:IJ>$^I;E.PFR/LO(A4SN-1B1*[I/D4Q+KW*^`B,Q*CAOCH=,N3
MSWN9%!8H138_>-4?>/N(V5D^=R67G)Y\HA2DXWDI;9%J[X(I8H#<69ALN@-2
M5S1((2$)23Z;A8F0`CK4^4RT)]<K($*X&]#T605+Y6/??)8$$Q7LJKT!NE%[
MZW>C^8$W.R6BD@(E-+_YF6!72/$>0DJ0NQ)D^"CS$5)!5`#`E?1N105RPF]$
M8(#Y">E*)\K/KKC,93))<"(I3)./5A<"XPG$_\<+IM1>\!?@Z%%/OXRI)44V
M:+T/DE<^2.G)!KV7$`+A;Z(,.:^@DL#=`0>@O3,BWNK4^N?SR7*4*@3A\R)5
M&?HI(;%\523'W&-@P'(.F*N2,R5+*6?/<J0C@>TD[%@M.SS-#JYI(A4G':CH
M_<A%5)73UFWLY8C6M<132BG![@3RDB8I.[$5%L";*J,4X)H)*0VY]DM@;)^&
M%"!V?O$7:`I`[H2HX$#238KO_',4,@G@6R1"RK-Y],@]50UA)1`,OBJ#%=\$
M-Z$6DX0!@I47)!.K)&0Y9K@0]+=OG,0;A+%+S@[21L/L0V;_L-=;M^C&A7=2
M%J"QZ(UT&@#`1,=B0/_9![Y@*!2U;&,2VG5Q)@T(:IFN9"&,5NISW*!EG/2(
MQR7#25,`73?]EL\-CM`-MIAE(#?,(3P)N=[.#T2;IM<(T)5QPG.4$`(!M'>H
MS5&ZN_VU]1278$;NIM[4/VVG%/Z1;K'+<Y8"Z2E4&]@ID\YS)0DL3DU/TG2Q
MUMBJ47A!_N0F-XY(>M*3F$0WJ$&`@;*Z&S+$OTUN3%`P<8-Y)"$'OAU>#HX`
M?6X0O;E+?M+R?])\$N7U,4$YM^UZ#H#A+E;/F3A-2C>33@AO/;NX&&PMNBW.
M-]19>3V2DI!02>XVU*!IN5N2,@++I`F4F=!@MU-R/,2E6.OB12A"^-5_)ZO_
MQ2$W.7.:GU^"='7E^PYW3-;,+HR;4P?U>*,T"]9PKU3K3!<G"3_YT2N9EQL'
M,DL[<RYR<T*F%'=Z9WF<%E@Z`QX#92H90GG^UTEX-"DBH`MGDU295AOIX@U"
M\2A+)10/XQW&%1174S>P%4XO-G-3P4HI@3B)`X.B<B:293$HH1J0M3"3$'QE
MP1UH8G\D<AO08EO)XP1JH'6W8%!(1!#S1%LCH@1,J$:20#$&8PMXY02#<75#
M@FUR9@M@&(9@N"^(@1O[,1Y`I`UZ`T5OPWQQ`88\Q$QA6!YI,QYGH0MB.(:^
M,2F*MA`:^`VD=3$ATW]8(@*VH!8D*!#?L0^VH`*T_Y,O_Y`60Y$7T(&(HQ44
MI`4Y\;-J+41]+>,3XR$R(6(PEA!SA'5<M%-9Q])^KU=O_G&"&K46!M53-L,S
MM!&*DY<RN)(5B851/&,6.5A6,X$RFY80MA!-_S`=EA!;7L,0Z#(<LJ`PF>5P
M;3->CA%_DZ8I?8A[P]$9>N*+W8(7AKA;X78SL`(?9F-1K79"0W42CT4KY0.#
MF#@=X-0XTR<<Q)47IYA_!*$$JW0T!B6#+Y5^4\0:NM!B^S%3MX$9-7.,(7.+
MB*@-R;$0?"$<VY!8OY.1X*ARMD083F`1A^@P6;5,`$.1Z5);.>-;RQ<1+'46
MVL`>]N$2<`<\D%0S7-,RCO]00@4@5]L@!P<A-I#A!&_S5`(A%[5E*:K3%8/5
M<A"7$Y*U#46P1[%T,F814]E6ANI"6;NU6>ZQE7FW)X0"%[4GC\QT64MU$IG1
M$!5U5=\`A"]%EBV'$A)%$"P'D(]!$)<@&0P17&:!.3:1CJ[!C:R4@B!"*`Q!
M,8B2F(JRF)!C6VFY$'^3*'6W%^UR&)H88`(A`I')F)S9&^_2=1^D!)O9F6V!
M*&F3+XF"?BVD-PF3)2G@!E9X*$:U$"6@>:3IE@2!1^DG)0+1)+ZY,%B"?'R$
M$+VS=8;4%0."0'@E(!U($H1&-"'0*BV8)0@T20-2=R#B,0$0G='Y?X_D*?-1
M9?7_,YY1YE^U82`&HBE`,B$44ITJ\V'AZ24U4C\C-D#<E2`_UH\R<FDI-B0\
M80`T<C[9V4"+P3YT$7/9(0)+DH18=V!#IP3TZ3D`ZF@#@6$"T"(M0GD*UC[G
M"4#NYD#(DYX\L3T`M'<<M#Q2%G3@TQU("1&&N1`4,DU$8UU24B%VAG6W<V<3
M9D)Z4@!N9J!>X6F3<:-L%V;R<6+9!F"=<B$5]IL6ZB*(M&89"3_Z.2,TTR->
MXCGZ.1\RZEE_AQ,U$C\QPCWP23U-$:+=TU\R4B04F1\(-%;G`T``]$'U!B+_
M4:;F,X!=(6%3,S[369YX4FG^64D$PA(K@F7YH08(`6=?_^-@$"I+<S8?CVE?
M('9S`I`A+7*A,#:0VHD7_P-=)1@`\U.BG98?H"EHX?FA)4*>[`.?EZ83-P*H
M]FFI]JEE>XF>W0,5!>*(BA0HZG,1$112NB,`!,*GCHA-__,07=B%!(4BO2D`
M7<>=]&<^?*IBC\:@$)0V!+0D2!*?0V($<A:6#-8A?\*HTQ$D?H:F8X(G5/9A
MX"="!%2?X26DY@-F6$I`KX,?W!,CWP:9?W*O1#=W"D9B(K1[ME:JDAH2(U,:
MP6E!R&=\G?9EM-1J<+6.+TH9C4:C`$N4\]>I%(>KC79\FR)_L7,[\VJM@/=Z
M+Y9F45&>$"2Q(T0]BGJ`QTEI&?_+/)NSJ0Y;2(+G'T@H'YAI>NZW=Q<+*)YD
M.J\32IN**1%(%=]F.TV"836S=PI;3*=&:U2;LX0$2(M1M)YB0I%D:_]W2,47
M:AC!2#K+)0,:>Z_'M4J[CBV::'@G$&(3%$.Q$O#&5P:K@+,6G)(&2'";,0L;
M)9"''<NX#:!3M0F!$CZ92B]6$$4;`*?A4@&PE!GW+6^@-V`(C_Y"AMNP"XR2
M+XUW"]<P+0+@!).0&[;@1;;@!$8P"7H3NN6C+]H`1:6;$Z+)FJ`[+?&A+Z)R
M3[0B"[9%48<7&_NB'F_A!JG;([Y+,9$C@E5(.=<`NFY@`"TS$H.UAHOBE_[Z
M=XZAAN;_=!M:>#AN@!_!TB-:QRQ%$"S:L1+_HGFSPA)J0!B?YD*&P2&ZT1*;
M@42S8A1@-2.L(0DJ4`)&(`?UDD4JTV_BI@V/QR+*D51JX0@ML1OLT736XR\'
M?"]YTRTRX@A:-A$ORA._%D.*8@TF(!@;UV_E$QB)8D:^<;[4!HG_0"(R\5;A
MD@(-59J'0D4B)R7;I@0AHRC0I'$TW'&[5`!,!HE8]`_M4QG;9H*+*5PIYP@E
MUYF3]5ISAQU7]%9IDD4EP45JHRA@.#;I4A/9J3C?(%T)9U_?<`WS0QB?Z[FB
M*5JB4IPG@2B(P8@KS!:]D1VQ,3,;K`T!8,!(PQ)RH0V[H(89*^R3NP%QVM!5
EW$MJ.\NT@#=JNY>U[*>R9,NP-+LQ#BA(8RMI29F4:B()`0$`.S\_
`
end
</TEXT>
</DOCUMENT>
</SUBMISSION>
